fluticasone furoate/umeclidinium/vilanterol vs Glycopyrronium (PT001)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

Glycopyrronium (PT001)

Developed by AstraZeneca

Phase 2/3 in Asthmasmall molecule
Partial signal

NCT03358147 · Phase 2/3 · completed

The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.

Next expected readout: May 2029 · NCT07525375 (registry estimate)

Reported efficacy

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)

Result source: NCT03358147

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolGlycopyrronium (PT001)
Severe exacerbations, annualised rate—Trial running · NCT04651777—Not reported
Trough FEV1, change0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
ACQ-5, change—Trial running · NCT04651777-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
OCS dose reduction—Trial running · NCT04651777—Not reported

Severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Glycopyrronium (PT001)
—Not reported

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
Glycopyrronium (PT001)
0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147

ACQ-5, change

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Glycopyrronium (PT001)
-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147

OCS dose reduction

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Glycopyrronium (PT001)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows · Glycopyrronium (PT001): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterol
Rows use multiple source trials
Glycopyrronium (PT001)
ACQ-7
absolute change · score
-0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 uga,b,c,d,e
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more dose
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
-0.78 vs -0.8 placebo score @ 24wk28.8 μga,b,c,d,e
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more doses
-0.73 vs -0.8 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-0.9 vs -0.8 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Dropout rate
7.7%100/31.25/25 mcgf
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
14.5%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
16.3%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
14.2%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Discontinued due to AEs
0.7%100/31.25/25 mcgf
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.3%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
3.8%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.9%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Serious AEs
4.4%100/31.25/25 mcgf
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.8%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
2.9%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.5%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Most frequent reported AEs
100/31.25/25 mcgf
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination
28.8 μg
upper respiratory tract infection 6% (placebo 8%)
nasopharyngitis 4.7% (placebo 3.4%)
sinusitis 4.3% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
14.4 μg
nasopharyngitis 6.3% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 2.9% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
7.2 μg
nasopharyngitis 7.1% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 1.7% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2/3.
  3. cPopulation context differs: baseline_threshold differs (acq6>=1.5, fev1_pct_predicted<85 versus fev1_pct_predicted<85, fev1_pct_predicted>40).
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 12 weeks versus 24 weeks.
  6. fPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

FEV1 Change 3 h 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcg
absolute change · L
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more results
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3

Glycopyrronium (PT001)

FEV1 AUC0-4 0.294 vs 0.24 placebo L @ 24wk28.8 μg
absolute change · L
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.284 vs 0.24 placebo L @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.308 vs 0.24 placebo L @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Moderate to Severe Exacerbation Rate Annualized 0.43 vs 0.55 placebo per year @ 24wk28.8 μg
event rate · per year
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.44 vs 0.55 placebo per year @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.41 vs 0.55 placebo per year @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-5 -0.87 vs -0.93 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.8 vs -0.93 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-1.02 vs -0.93 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
AQLQ 0.89 vs 0.96 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.9 vs 0.96 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
1.02 vs 0.96 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Glycopyrronium (PT001)'s landscape